Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04118166 · ClinicalTrials.gov registry record · Phase 2
Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma
A Phase 2 study of Soft Tissue Sarcoma, sponsored by Kristen Ganjoo.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04118166 is a Phase 2 study of Soft Tissue Sarcoma that has completed, run by Kristen Ganjoo. The registered enrollment target is 30 participants, below the 78-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04118166, a Phase 2 study of Soft Tissue Sarcoma, has completed, sponsored by Kristen Ganjoo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this Phase 2 study is to 1. find out if the study drugs (ipilimumab plus nivolumab) in combination with cryotherapy will help participants with metastatic or locally advanced soft tissue sarcoma;. 2. find out how safe are ipilimumab plus nivolumab given in combination with cryotherapy, and what side effects may be related to treatment. 3. find out how do the study drugs in combination with cryotherapy work in soft tissue sarcoma.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- PROCEDURE Cryoablation
Study Locations (1)
California
- Stanford Medical Center - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-10-01 |
| Est. Completion | 2022-04-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04118166
The ClinicalTrials.gov registry entry for NCT04118166 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 78-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (62% lower). The listed sponsor is Kristen Ganjoo, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Soft Tissue Sarcoma appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT04118166 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04118166 about?
NCT04118166 is a clinical study titled "Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma". The purpose of this Phase 2 study is to 1. find out if the study drugs (ipilimumab plus nivolumab) in combination with cryotherapy will help participants with metastatic or locally advanced soft tissue sarcoma;. 2. find out how safe are ipilimumab plus nivolumab given in combination with cryotherap...
What is the current status of trial NCT04118166?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2019-10-01. Estimated completion is 2022-04-26.
What conditions does trial NCT04118166 study?
This clinical trial studies the following conditions: Soft Tissue Sarcoma.
What interventions are being tested in trial NCT04118166?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Cryoablation (PROCEDURE).
Who is sponsoring clinical trial NCT04118166?
This trial is sponsored by Kristen Ganjoo, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04118166 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas
RECRUITING · Phase 2
-
SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma
RECRUITING · Phase 2
-
5-Day Preoperative Radiation for Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.